CNTB Research | Milton Maxwell

Upcoming Earnings

Report date

≈ -

Key Stats

Market Cap

88.24M

P/E (TTM)

-

Basic EPS (TTM)

-0.81

Dividend Yield

0%

Recent Filings

8-K

9/16/25Sep 16, 2025

10-Q

8/13/25Aug 13, 2025

8-K

8/13/25Aug 13, 2025

8-K

7/22/25Jul 22, 2025

8-K

7/21/25Jul 21, 2025

About

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of inflammatory diseases in the United States. The company's lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is in Phase 3 studies for the treatment of inflammatory diseases such as atopic dermatitis and asthma. Connect Biopharma Holdings Limited was founded in 2012 and is headquartered in San Diego, California.

CEO

Dr. Barry D. Quart Pharm.D.

IPO

3/19/2021

Website

https://www.connectbiopharm.com

Employees

62

Sector

Healthcare

Industry

Biotechnology